本帖最后由 towersimper 于 2011-8-12 09:11 编辑 ) e- {" j! p3 s; S2 W; E; N
1 s7 F/ C! T: y$ F- F9 D J$ }! l; S
2009年伪造数据的两篇关于肿瘤抑制物HIC1的研究文章被撤回
* L z- y8 g! \8 jSheng Wang leaves the Boston University School of Medicine and agrees to retract two published studies.
5 x$ q) i% l5 b9 W* t$ z! k$ K' ]3 Z: P) B# ~/ e7 n" h" N/ T: Q
Sheng Wang, assistant professor of medicine at the Boston University School of Medicine (BUSM) Cancer Research Center until last month, committed research misconduct, the Department of Health and Human Services’ Office of Research Integrity (ORI) announced last Friday (August 5). Specifically, the ORI determined that Wang fabricated data published in two 2009 papers in the journals Molecular Endocrinology (ME) and Oncogene, both of which Wang has agreed to retract.
4 ^) o& ~, K$ o3 L- d% J
' t1 Z/ S- f4 Q l* EThe falsified figures show real-time PCR data—a technique used to locate genes and quantify their expression—and chromatin immunoprecipitation (ChIP)—used to determine how and where proteins interact with DNA in the cell—to support their conclusions about the HIC1 protein’s pivotal role in tumor suppression.- X% X" Z/ v S
% P: {6 E$ f3 u8 J% bHIC1 (“hypermethylated in cancer 1”) is a protein known to suppress cell growth. The gene that encodes HIC1 was recently shown to be epigenetically disrupted in human tumors, and its expression has been linked to better outcomes in some breast cancers. Using both PCR and ChIP, Wang and his colleagues showed that HIC1 acts via a downstream protein called Brg1. In a follow up study, the researchers found that HIC1 is required for estrogen neutralizers—which combat certain breast cancers—to effectively suppress tumor growth.
' Q m z1 H. x# t9 n `9 R* O9 p* a( l0 x
The fabricated data affected six of the eight figures in the Oncogene paper, which has been cited 9 times, according to ISI, and six of the seven figures in the ME paper, which has not been cited. Though neither paper has yet been retracted, and neither journal could confirm whether it was considering such a move, Wang must retract them according to his agreement with the ORI. “The retraction of the articles is in accordance with the decision reached by the ORI,” Maria Pantages Ober, director of communications for BUSM, said in a statement.! U* A0 {' i3 ^5 {2 ]
5 q. m! H- Z5 ], a- e6 H
But researchers say the impending retractions will not significantly impact the field’s understanding of HIC1’s role in tumor suppression, as the papers’ basic findings have been shown in other studies.8 {1 o. s# [0 @% Z4 q) o* N
Q. q6 U0 v+ [: N( F伪造数据的两篇论文为：
t- G3 f( ?$ wB Zhang, K J Chambers, D Leprince, D V Faller and S Wang, "Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth controlHIC1 requires Brg1 for transcription regulation", Oncogene 28, 651-661 (5 February 2009) | doi:10.1038/onc.2008.419.3 o6 ^/ s" S' u) O* A! @
( Z: Z: A+ w1 S9 ~. d2 E2 r
Baohua Zhang, Douglas V. Faller and Sheng Wang, "HIC1 Regulates Tumor Cell Responses to Endocrine Therapies", Molecular Endocrinology December 1, 2009 vol. 23 no. 12 2075-2085. |
发表于 2011-8-12 09:10
